BioInvent International AB (BINV) AI Stock Analysis

• Market Cap: $1.88B
• Dividend Yield: N/A
• Average Volume (3M): 95.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: 382.81%
• EPS Growth: 23.87%
• Country: SE
• Employees: 118
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.59
• Shares Outstanding: 65,804,360
• 10 Day Avg. Volume: 86,796
• 30 Day Avg. Volume: 95,770
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 5.83
• Enterprise Value/Gross Profit: 5.83
• Enterprise Value/Ebitda: -4.91
• 1Y Price Target: $90.19
• Price Target Upside: 229.18% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: kr29.00 ▲(5.84% Upside)

BioInvent International AB's overall stock score is primarily impacted by its strong revenue growth but offset by significant challenges in profitability and cash flow. The technical analysis indicates a bearish trend, and the negative P/E ratio highlights valuation concerns. The absence of earnings call data and corporate events means these factors do not influence the score.

BioInvent International AB Business Overview & Revenue Model

Company Description

BioInvent International AB (BINV) is a biotechnology company based in Sweden, specializing in the development of innovative antibody therapies for the treatment of cancer and other diseases. The company focuses on the discovery and development of novel therapeutic antibodies, leveraging its proprietary technology platform to create targeted treatments that aim to improve patient outcomes. BioInvent operates primarily within the pharmaceutical and biotechnology sectors, with a strong emphasis on advancing its pipeline of drug candidates into clinical trials.

How the Company Makes Money

BioInvent generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which often involve licensing agreements and milestone payments related to the development of its therapeutic candidates. Additionally, the company may earn royalties from the sales of products developed under these partnerships. Research funding and grants from governmental and non-governmental organizations also contribute to its revenue streams. The company’s financial health is bolstered by successful clinical trial results that can lead to further investment and collaboration opportunities in the biotechnology sector.

BioInvent International AB Financial Statement Overview

Summary

BioInvent International AB faces significant financial challenges, with declining revenues and persistent losses impacting profitability. The balance sheet remains a relative strength due to solid equity and a low debt burden. However, the company's inability to generate positive cash flow from operations raises concerns about its long-term sustainability.

Income Statement

The company has experienced a severe decline in revenue over the past few years, with TTM (Trailing-Twelve-Months) revenue significantly lower than previous years. Gross profit margins have remained constant at 100%, indicating that all revenue contributes directly to gross profit. However, the net profit margin is deeply negative, reflecting substantial operating losses. The EBIT and EBITDA margins are also negative, highlighting significant operational challenges.

Balance Sheet

The company maintains a strong equity position with an equity ratio of approximately 89% in the TTM period. The debt-to-equity ratio is low, suggesting limited reliance on debt financing. However, the substantial negative net income impacts the return on equity, which remains negative. The company's cash position remains strong, providing some stability amidst operational challenges.

Cash Flow

Operating cash flow has been consistently negative, indicating that the company is not generating enough cash from operations to cover its expenses. Free cash flow has also declined, reflecting increased operational and capital expenditure pressures. Despite these challenges, the company has managed to maintain a positive cash position through financing activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	254.29M	44.69M	71.46M	326.13M	19.38M	147.37M
Gross Profit	254.29M	44.69M	71.46M	326.13M	19.38M	147.37M
EBITDA	-301.77M	-409.38M	-312.71M	-27.13M	-263.32M	-63.99M
Net Income	-291.95M	-429.38M	-330.30M	-34.09M	-278.96M	-76.67M
Balance Sheet
Total Assets	916.67M	989.24M	1.40B	1.71B	1.45B	802.64M
Cash, Cash Equivalents and Short-Term Investments	797.52M	867.16M	1.07B	1.02B	1.08B	729.27M
Total Debt	12.94M	17.41M	23.24M	26.96M	28.37M	11.60M
Total Liabilities	105.93M	103.42M	90.45M	106.09M	80.32M	59.14M
Stockholders Equity	810.74M	885.82M	1.31B	1.61B	1.37B	743.50M
Cash Flow
Free Cash Flow	-255.56M	-390.50M	-355.00M	-53.60M	-259.10M	-69.32M
Operating Cash Flow	-248.58M	-380.47M	-341.69M	-41.23M	-245.84M	-62.62M
Investing Cash Flow	206.37M	564.35M	59.68M	-628.85M	-467.54M	-6.70M
Financing Cash Flow	-8.79M	-8.46M	23.14M	273.49M	894.87M	644.62M

BioInvent International AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 27.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BINV, the sentiment is Negative. The current price of 27.4 is below the 20-day moving average (MA) of 28.95, below the 50-day MA of 32.10, and below the 200-day MA of 31.92, indicating a bearish trend. The MACD of -1.02 indicates Negative momentum. The RSI at 38.61 is Neutral, neither overbought nor oversold. The STOCH value of 51.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BINV.

BioInvent International AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	68 Neutral	€1.69B	6.14	114.45%	―	1265.46%	―
HNSA	54 Neutral	kr3.99B	―	―	―	20.12%	40.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XSPRAY	47 Neutral	€1.12B	―	-41.54%	―	―	0.57%
VICO	45 Neutral	€2.89B	―	-55.23%	―	-92.57%	-7.72%
BINV	41 Neutral	$1.88B	―	-28.70%	―	382.81%	23.87%
CANTA	31 Underperform	kr646.39M	―	-275.87%	―	―	38.99%

BioInvent International AB Corporate Events

BioInvent and Transgene to Present Promising BT-001 Study Results at ESMO 2025

BioInvent International AB and Transgene have announced the presentation of updated data from the Phase 1 part of their ongoing Phase 1/2a study of the oncolytic virus BT-001 at the ESMO 2025 Annual Meeting. The study, which involves using BT-001 in combination with pembrolizumab, has shown promising results, with clinical responses observed in some patients with advanced solid tumors. This development could enhance BioInvent’s position in the cancer immunotherapy market and provide new treatment options for patients with refractory tumors.

BioInvent’s BI-1808 Shows Promising Results in Phase 2a CTCL Study

BioInvent International AB has announced promising results from its Phase 2a study of BI-1808, a monotherapy for cutaneous T-cell lymphoma (CTCL), showing a 100% disease control rate and significant immune activation. The study, which will be presented at the EHA 2025 congress, highlights the potential of BI-1808 as an immune-modulating therapy with a favorable safety profile, marking a significant milestone in BioInvent’s mission to develop transformative cancer therapies.

BioInvent Reports Positive Phase 1 Results for Cancer Therapy

BioInvent International AB has announced promising results from its Phase 1 study of BI-1206 in combination with KEYTRUDA® (pembrolizumab) for solid tumors, showing significant clinical activity including complete and partial responses. The company plans to initiate Phase 2a expansion cohorts to further investigate this combination in patients with advanced non-small cell lung cancer and uveal melanoma, potentially improving treatment outcomes and addressing unmet medical needs in these cancers.

BioInvent Showcases BI-1910 Development at PAGE 2025

BioInvent International AB announced the presentation of a poster at the PAGE 2025 meeting in Thessaloniki, Greece, highlighting the early clinical development of its anti-TNFR2 drug candidate, BI-1910. The company successfully developed a population model to characterize the pharmacokinetics and pharmacodynamics of BI-1910, which will aid in dose selection for upcoming Phase 2a studies. These studies, planned for the second half of 2025, will evaluate BI-1910 as a single agent and in combination with pembrolizumab for various tumor types. The announcement underscores BioInvent’s progress in cancer immunotherapy and its potential impact on clinical utility and market potential.

BioInvent Sells Mezagitamab Rights to XOMA for $30 Million

BioInvent International AB has sold its future royalty and milestone rights for the cancer drug mezagitamab to XOMA Royalty for up to USD 30 million. This transaction provides BioInvent with non-dilutive capital to advance its drug development programs and reflects XOMA’s increased interest in mezagitamab, enhancing its royalty portfolio with potential future earnings from the drug’s commercial success.

BioInvent Reports Promising Phase 2a Results for BI-1808 in CTCL

BioInvent International AB has announced promising results from its ongoing Phase 2a study of BI-1808, a monotherapy for Cutaneous T-cell Lymphoma (CTCL). The study has shown encouraging clinical activity with one complete response, three partial responses, and four stable diseases among eight evaluable patients. The treatment demonstrated strong immune activation and was well tolerated, with no severe adverse events reported. These findings, to be presented at the EHA 2025 congress, support further development of BI-1808 as a potential novel treatment option for CTCL, reinforced by its recent Fast Track and Orphan Drug Designation by the FDA.

BioInvent Reports Promising Phase 2a Data for NHL Treatment

BioInvent International AB announced promising preliminary data from its ongoing Phase 2a study of a triple combination therapy involving BI-1206, rituximab, and Calquence for treating non-Hodgkin’s lymphoma (NHL). The data showed a 63% objective response rate among the first eight patients, with two complete responses and three partial responses, indicating potential improvements in treatment outcomes and resistance management. The combination therapy has been well tolerated, and BioInvent plans to advance its clinical development, highlighting the potential impact on NHL treatment and the company’s position in cancer immunotherapy.